Miragen Therapeutics, Inc. [MGEN] is following upward trend in the market concluded with the last trading session. The shares of the Healthcare sector company has a current value of $1.82 after MGEN shares went up by 24.64% during the last trading session. One of the reasons why Healthcare stocks may go bullish is increased momentum in the press.
Miragen Therapeutics, Inc. [NASDAQ:MGEN]: Analyst Rating and Earnings
Its stock price has been found in the range of 0.44 to 3.80. This is compared to its latest closing price of $1.46.
Keep an eye out for the next scheduled publication date for this company’s financial results, which are expected to be released on Wed 11 Mar (In 43 Days).
Fundamental Analysis of Miragen Therapeutics, Inc. [MGEN]
Now let’s turn to look at profitability: with a current Operating Margin for Miragen Therapeutics, Inc. [MGEN] sitting at -394.51.
This company’s Return on Total Capital is -60.11, and its Return on Invested Capital has reached -53.70%. Its Return on Equity is -72.79, and its Return on Assets is -55.14. These metrics suggest that this Miragen Therapeutics, Inc. does a poor job of managing its assets, and likely won’t be able to provide successful business outcomes for its investors in the near term.
Turning to investigate this organization’s capital structure, Miragen Therapeutics, Inc. [MGEN] has generated a Total Debt to Total Equity ratio of 20.06. Similarly, its Total Debt to Total Capital is 16.71, while its Total Debt to Total Assets stands at 15.57. Looking toward the future, this publicly-traded company’s Long-Term Debt to Equity is -37.90, and its Long-Term Debt to Total Capital is 15.59.
What about valuation? This company’s Enterprise Value to EBITDA is 1.06. The Enterprise Value to Sales for this firm is now -8.61, and its Total Debt to Enterprise Value stands at 0.27. Miragen Therapeutics, Inc. [MGEN] has a Price to Book Ratio of 1.82.
Shifting the focus to workforce efficiency, Miragen Therapeutics, Inc. [MGEN] earns $104,825 for each employee under its payroll. Similarly, this company’s Receivables Turnover is 11.33 and its Total Asset Turnover is 0.14. This publicly-traded organization’s liquidity data is also interesting: its Quick Ratio is 9.71 and its Current Ratio is 9.71. This company, considering these metrics, has a healthy ratio between its short-term liquid assets and its short-term liabilities, making it a less risky investment.
Miragen Therapeutics, Inc. [MGEN] has 32.22M shares outstanding, amounting to a total market cap of $47.04M. Its stock price has been found in the range of 0.44 to 3.80. At its current price, it has moved down by -52.11% from its 52-week high, and it has moved up 313.59% from its 52-week low.
This stock’s Beta value is currently 1.50, which indicates that it is 40.56% more volatile that the wider market. This stock’s Relative Strength Index (RSI) is at 87.36. This RSI suggests that Miragen Therapeutics, Inc. is currently Overbought.
Conclusion: Is Miragen Therapeutics, Inc. [MGEN] a Reliable Buy?
Shares of Miragen Therapeutics, Inc. [MGEN], overall, appear to be a solid investment option, with Wall Street analysts expecting its price to rise considerably in the next 12 months. This company generates high value from the labor resources and other capital it has available, and while it has heavy Long-Term Debt to Equity, the majority of the metrics point to this investment being highly attractive.